ByteDance spin-off Anew Labs raises US$290m as AI drug developers enjoy fundraising boom

Anew Labs' US$290 million raise, valuing it at US$1.5 billion, underscores China's aggressive push into AI drug discovery. ByteDance's continued 56 percent stake shows a commitment to this sector. This reflects a broader trend of major Chinese tech firms incubating and backing AI ventures. They seek to diversify beyond core internet services.

The focus on biomolecular prediction, including an open-source reproduction of AlphaFold 3, positions Anew Labs as a direct challenger to Google DeepMind and Isomorphic Labs. This competition is crucial for China's biotech self-sufficiency. It also provides domestic pharmaceutical companies with advanced tools. The funding boom will accelerate drug development within the region.

The test for Anew Labs is its ability to translate model predictions into tangible drug candidates. Many AI drug discovery firms face this hurdle. Investors will watch for clinical trial progress and pipeline development. This will validate the US$1.5 billion valuation.